VBVendula Belackova

Vendula Belackova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vendula Belackova has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Getting “The whole picture”: A review of international research on the outcomes of regulated cannabis supply

    by Vendula Belackova, Benjamin Petruzelka, Jakub Cihak, Jana Michailidu, Viktor Mravcik


  • Open Access

    Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost

    by Craig Rodgers, Krista J Siefried, Alison Ritter, Vendula Belackova, Carla Treloar, Marianne Jauncey, Nadine Ezard, Darren Roberts, Maureen Steele, Willem van Den Brink, et al.

    Introduction Supervised injectable opioid treatment (SIOT) is an evidence-based intervention targeting opioid-dependent people for whom existing treatments have been ineffective. This project will primarily assess the feasibility and the acceptability of time-limited SIOT using injectable hydromorphone delivered in an existing Australian public opioid treatment programme, with secondary outcomes of safety, cost, changes in drug use and other health outcomes. If feasible, the goal is to scale up the intervention to be more widely available in Australia. Methods and analysis Between 20 and 30 participants will be offered two times per day hydromorphone to inject under direct observation, in addition to their current opioid agonist treatment (OAT), for up to 2 years. At the end of 2 years of supervised hydromorphone treatment, participants will be continued on standard OAT only. Informed consent will be obtained from all participants included in the study. This is a single-site, uncontrolled, open-label study where quantitative and qualitative interview data will be collected at baseline, 12 months and lastly at 3 months following their final hydromorphone dose. The main outcome measures are feasibility, as assessed by recruitment, retention and participation in treatment, and acceptability to participants, clinic staff and other stakeholders assessed by qualitative interviews. Secondary outcome measures of safety, as assessed by adverse events, and cost will also be assessed, as well as a range of other drug and health outcomes. Ethics and dissemination This study received ethical approval from the St Vincent’s Hospital Human Research Ethics Committee (2019/ETH00418). This will be the first study of time-limited SIOT in the Australian setting. All results will be submitted to peer-reviewed journals, scientific conferences and local practice meetings. A preliminary report on outcomes will also be presented to local health policy makers. A consumer and community forum will also be held to feedback results to a broader audience. Trial registration number ACTRN12621001729819.


  • Open Access

    Correction: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

    by Lucas Wiessing, Prakashini Banka-Cullen, M. Gabriela Barbaglia, Vendula Belackova, Saed A. S. Belbaisi, Peter Blanken, Patrizia Carrieri, Catherine Comiskey, Daniel Dacosta-Sánchez, Geert Dom, et al.

  • Open Access

    Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

    by Lucas Wiessing, Prakashini Banka-Cullen, M. Gabriela Barbaglia, Vendula Belackova, Saed A. S. Belbaisi, Peter Blanken, Patrizia Carrieri, Catherine Comiskey, Daniel Dacosta-Sánchez, Geert Dom, et al.

    Non-medical opioid use is a major public health concern causing high mortality. While opioid agonist maintenance treatment (OMT) is a key life-saving intervention, there is (a) no international consensus on opioid treatment outcomes and (b) few opioid treatment outcome studies include key (public) health outcomes, such as overdose or HIV/hepatitis C. We report the rationale and study protocol for, and preliminary results of, an ongoing international OMT outcomes consensus study that aims to address this double gap (n = 110 collaborating experts from 32 countries, plus a n = 477 Delphi evaluation panel from 26 of those countries: 58% male–41% female; 47% OMT patients–53% OMT professionals). We present a first draft of a patient interview guide (including a ‘clinical form’) to monitor OMT outcomes in six domains. The form appears to be well accepted and feasible in early testing. Through this, we aim to enhance the quality of and access to OMT, and improve the survival, health and quality of life of people who use opioids, while promoting non-stigmatising patient-physician relationships.


  • Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross‐sectional study in three Australian cities

    by Suzanne Nielsen, Paul Sanfilippo, Vendula Belackova, Carolyn Day, Ed Silins, Nicholas Lintzeris, Raimondo Bruno, Jason Grebely, Kari Lancaster, Robert Ali, et al.

    Background and aims: Not all people experiencing opioid dependence benefit from oral opioid agonist treatment. The aim of this study was to examine perceptions of (supervised) injectable opioid agonist treatment (iOAT) (described as ‘an opioid similar to heroin self‐injected at a clinic several times a day’) among people who regularly use opioids and determine how common iOAT eligibility criteria accord with interest in iOAT.Design: Cross‐sectional surveySetting: Sydney, Melbourne and Hobart, AustraliaParticipants: A total of 344 people (63% male) who use opioids regularly and had ever injected opioids, interviewed December 2017–March 2018. The mean age of participants was 41.5 years [standard deviation (SD) = 8.5].Measurements: Primary outcome measures were interest in iOAT, factors associated with interest and the proportion of participants who would be eligible using common criteria from trials and guidelines. We examined willingness to travel for iOAT, medication preferences and perspectives on whom should receive iOAT.Findings: Overall, 53% of participants (n = 182) believed that iOAT would be a good treatment option for them. Participants who believed that iOAT was a good treatment option for them were more likely to be male [adjusted odds ratio (aOR) = 1.76, 95% confidence interval (CI) = 1.10–2.82], have used heroin in the past month (aOR = 6.03, 95% CI = 2.86–12.71), currently regularly inject opioids (aOR = 1.84, 95% CI = 1.16–2.91) and have met ICD‐10 criteria for opioid dependence (aOR = 3.46, 95% CI = 1.65–7.24). Those interested in iOAT had commenced more treatment episodes (aOR =1.06, 95% CI = 1.00–1.12). Among those interested in iOAT (n = 182), 26% (n = 48) met common eligibility criteria for iOAT.Conclusions: Interest in injectable opioid agonist treatment does not appear to be universal among people who regularly use opioids. Among study participants who expressed interest in injectable opioid agonist treatment, most did not meet common eligibility criteria.


  • How to ask about the use of new psychoactive substances to increase the validity of results in self‐report prevalence surveys

    by Eva Drapalova, Vendula Belackova, Agnès Cadet‐Taïrou

    Introduction and Aims: New psychoactive substances (NPS) represent hundreds of novel compounds. However, the general public might not be familiar with the overarching term NPS. This can result in both under‐ and over‐reporting of NPS use.Design and Methods: The study analysed the last‐year prevalence of NPS use in an online survey conducted across I‐TREND project countries (the Czech Republic, the Netherlands and Poland). Self‐reported NPS use was assessed within two types of questions—a generic and a checklist question. We analysed prevalence for each question separately, incorporated the free‐text probe ‘other’ that followed them, and combined the two questions into a conservative and an inclusive estimate.Results: Including free‐text responses to the ‘other’ categories increased prevalence of NPS use (from 51% to 56% for the checklist question and 25% to 32% for the generic question). Taking an inclusive approach to estimating prevalence (i.e. indicating NPS use in either a generic list or from the checklist) yielded a higher prevalence estimate (60%, 95% confidence interval 58–62%), compared to a more conservative approach in which NPS use had to be affirmed by both questions (27%, 95% confidence interval 26–29%).Discussion and Conclusions: Generic questions might lead to notably lower estimates of self‐reported NPS use in comparison to checklists. However, creating relevant checklists is challenging and lengthy survey instruments have limitations. Further surveys might benefit from featuring a combination of the strategies used in this study—a single (generic) question involving a number of locally specific NPSs and a free‐text ‘other’ probe.


  • “The Good, the Bad, and the Ugly Weed”: How Consumers in Four Different Policy Settings Define the Quality of Illicit Cannabis

    by Vendula Belackova

    With proliferating efforts to regulate the quality of cannabis on legalized markets, and recent discussions about drug quality assessment by darknet buyers, it seems timely to explore definitions of the quality of cannabis among consumers. An inductive analysis of in-depth interviews with people who had used cannabis in the past 12 months was conducted, which focused on the respondents’ subjective definitions and assessments of the quality of cannabis. The data are drawn from convenience samples in four localities (Florida [United States], Czechia, Spain, and New South Wales [Australia]) where cannabis was illegal or decriminalized. The findings suggest that the respondents across all four localities used a range of visual and sensory indicators to assess the quality of cannabis. For many respondents, these were independent indicators of the quality of cannabis suggesting that cannabis was not merely an “experience” good. For others, visual and sensory assessments were used as indirect indicators of quality in that they represented the effect of the cannabis. The desired effect was more complex than simple potency (strength) and several respondents preferred mild and not-sedating cannabis. Across the four localities, the respondents also included “proxy” indicators of the safety of cannabis in their definitions of quality. In other words, high-quality cannabis was defined as not causing excessive intoxication or physical harm. Altogether, cannabis was a specific “credence” good when its quality was seen as a result of cultivation techniques, production location, or producers’ (profit) motivations - depending on the locality. These findings suggest that cannabis policies that regulate the cultivation process can be relevant to people who use cannabis. Given that consumers take the safety of cannabis into consideration when assessing its quality, their involvement in the development of quality standards is warranted. Consumer-led self-regulation should also be considered in policies that seek to regulate cannabis supply.


  • Open Access

    Safer injecting facilities—is the research there? A comment on Caulkins et al. (2019)

    by Vendula Belackova, Allison M. Salmon, Marianne Jauncey, Carolyn A. Day